中国生化药物杂志
中國生化藥物雜誌
중국생화약물잡지
CHINESE JOURNAL OF BIOCHEMICAL PHARMACEUTICS
2015年
7期
92-94
,共3页
林冠霞%郑建玮%章金艳%史美娜
林冠霞%鄭建瑋%章金豔%史美娜
림관하%정건위%장금염%사미나
美沙拉秦缓释片%硫唑嘌呤%小肠克隆恩病%临床疗效
美沙拉秦緩釋片%硫唑嘌呤%小腸剋隆恩病%臨床療效
미사랍진완석편%류서표령%소장극륭은병%림상료효
mesalazine sustained release tablets%azathioprine%intestinal Crohn’s disease%clinical efficacy
目的:探讨美沙拉秦缓释片联合硫唑嘌呤在小肠克隆恩病治疗中的临床疗效。方法选取本院收治的小肠克隆恩病患者60例,随机分为观察组和对照组,每组30例。观察组给予美沙拉秦缓释片1.5 mg~2.0 mg/( kg? d),1~2次/天,另联合硫唑嘌呤1克/次,2次/天治疗;对照组给予单独硫唑嘌呤治疗1克/次,2次/天,2组均治疗30周,比较2组治疗后活动指数评分、临床缓解率、黏膜愈合率,分析治疗前后血液生化指标,并记录治疗期间不良反应情况。结果2组患者治疗后活动指数评分较治疗前有明显下降( P<0.05),但观察组患者下降较对照组更显著( P<0.05);观察组治疗后完全缓解率优于对照组( P<0.05);2组患者治疗后的WBC计数、ESR水平和CRP水平较治疗前均明显降低(P<0.05),且观察组较对照组明显(P<0.05);2组AIL水平和TLB水平较治疗前明显升高(P<0.05),但观察组升高较对照组明显(P<0.05);观察组患者不良发生率为26.67%,明显高于对照组的6.67%( P<0.05)。结论美沙拉秦缓释片联合硫唑嘌呤治疗小肠克隆恩病较单独使用硫唑嘌呤治疗更有效,可以显著提高治疗效果,但不良反应发生率较高。
目的:探討美沙拉秦緩釋片聯閤硫唑嘌呤在小腸剋隆恩病治療中的臨床療效。方法選取本院收治的小腸剋隆恩病患者60例,隨機分為觀察組和對照組,每組30例。觀察組給予美沙拉秦緩釋片1.5 mg~2.0 mg/( kg? d),1~2次/天,另聯閤硫唑嘌呤1剋/次,2次/天治療;對照組給予單獨硫唑嘌呤治療1剋/次,2次/天,2組均治療30週,比較2組治療後活動指數評分、臨床緩解率、黏膜愈閤率,分析治療前後血液生化指標,併記錄治療期間不良反應情況。結果2組患者治療後活動指數評分較治療前有明顯下降( P<0.05),但觀察組患者下降較對照組更顯著( P<0.05);觀察組治療後完全緩解率優于對照組( P<0.05);2組患者治療後的WBC計數、ESR水平和CRP水平較治療前均明顯降低(P<0.05),且觀察組較對照組明顯(P<0.05);2組AIL水平和TLB水平較治療前明顯升高(P<0.05),但觀察組升高較對照組明顯(P<0.05);觀察組患者不良髮生率為26.67%,明顯高于對照組的6.67%( P<0.05)。結論美沙拉秦緩釋片聯閤硫唑嘌呤治療小腸剋隆恩病較單獨使用硫唑嘌呤治療更有效,可以顯著提高治療效果,但不良反應髮生率較高。
목적:탐토미사랍진완석편연합류서표령재소장극륭은병치료중적림상료효。방법선취본원수치적소장극륭은병환자60례,수궤분위관찰조화대조조,매조30례。관찰조급여미사랍진완석편1.5 mg~2.0 mg/( kg? d),1~2차/천,령연합류서표령1극/차,2차/천치료;대조조급여단독류서표령치료1극/차,2차/천,2조균치료30주,비교2조치료후활동지수평분、림상완해솔、점막유합솔,분석치료전후혈액생화지표,병기록치료기간불량반응정황。결과2조환자치료후활동지수평분교치료전유명현하강( P<0.05),단관찰조환자하강교대조조경현저( P<0.05);관찰조치료후완전완해솔우우대조조( P<0.05);2조환자치료후적WBC계수、ESR수평화CRP수평교치료전균명현강저(P<0.05),차관찰조교대조조명현(P<0.05);2조AIL수평화TLB수평교치료전명현승고(P<0.05),단관찰조승고교대조조명현(P<0.05);관찰조환자불량발생솔위26.67%,명현고우대조조적6.67%( P<0.05)。결론미사랍진완석편연합류서표령치료소장극륭은병교단독사용류서표령치료경유효,가이현저제고치료효과,단불량반응발생솔교고。
Objective To evaluate the clinical efficacy of mesalazine sustained-release tablets in combination with azathioprine in the small intestine Crohn’s disease therapy.Methods 60 cases of small intestinal Crohn disease patients were randomly divided into two groups and the control group 30 cases.Observation group mesalazine sustained-release tablets 1.5 mg ~2.0 mg/( kg? d ) , 1 ~2 times/d, the other in combination with azathioprine 1 g/times, 2 times/d treatment;control group received azathioprine alone 1 g/times, 2 times/d, both groups were treated for 30 weeks after treatment were compared activity index score, clinical remission rate, mucosal healing rate, blood biochemical parameters before and after treatment, and record adverse reactions during treatment.ResuIts The two groups of patients after treatment than before treatment activity index score decreased significantly (P<0.05), but the observation group were more than the control group decreased significantly (P<0.05); observation group complete remission rate and mucosal healing rates better than the control group (P<0.05);the WBC count, ESR and CRP level were lower than before treatment (P<0.05);AIL two levels and TLB levels were significantly increased compared with that before treatment (P<0.01), but the observation group was significantly higher than that in the control group ( P<0.05 ); the incidence of adverse observation group were 26.67%, significantly higher than the 6.67%( P<0.05 ) .ConcIusion Mesalazine sustained-release tablets in combination with azathioprine therapy compared with small bowel Crohn’s disease treatment is more effective azathioprine alone, can significantly improve the therapeutic effect, but incidence of adverse reactions is higher.